Immunocore Holdings plc IMCR · Stock Open Immunocore Holdings plc in new tab
Immunocore Holdings plc Analysis (IMCR)
Is Immunocore Holdings plc a good investment? Immunocore Holdings plc (IMCR) is currently trading at 32.43 USD. Market analysts have a consensus price target of 63.49 USD. This suggests a potential upside from current levels.
Earnings Schedule: Immunocore Holdings plc is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.52.
Investor FAQ
Does Immunocore Holdings plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Immunocore Holdings plc?
Immunocore Holdings plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.56.
Company Profile
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Community Discussion